Noticias de ABT_US
Noticias del mercado
Últimas noticias sobre ABT_US — 804 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Abbott (ABT) wins FDA approval for TactiFlex Duo, a cardiac ablation device designed for complex cases of atrial fibrillation. Read more here.
Abbott Laboratories stock is trading against July 16, 2026 results, with Q2 revenue at USD 12.59 bil
Abbott Laboratories (NYSE:ABT) is in focus as healthcare stocks prepare for the next U.S. session after the Labor Day market closure.
Abbott Laboratories stock continues to trade at a valuation premium supported by recent earnings mom
Abbott Laboratories stock traded at $108.29 on September 4, 2026, after a July 16 quarter that deliv
In recent weeks, Abbott Laboratories received FDA authorization for its Libre Duo 10 Day dual glucose‑ketone sensor, advanced its TactiFlex Duo AFib ablation catheter toward U.S. approval, launched Similac 360 Total Care Made With Whole Milk in ready‑to‑feed form, and partnered with the Colorectal Cancer Alliance on an at‑home screening education hub. Taken together, these moves highlight how Abbott is extending its reach across diabetes care, cardiac rhythm management, infant nutrition, and...
_07_03_2026_03_50_21_133108.jpg)
Abbott Laboratories stock is trading modestly higher as of September 4, 2026, while investors weigh
Ferguson Wellman Capital Management Inc. trimmed its position in Abbott Laboratories (NYSE:ABT - Free Report) by 77.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,171 shares of the healthcare product maker's stock after selling 136,385 shares during the...
Página 27 de 41